CMRAW

Comera Life Sciences Holdings, Inc. is an early-stage life sciences company dedicated to developing its own innovative therapeutics. These treatments leverage its unique SQore formulation platform, which is engineered to convert biologics typically administered intravenously (IV) into convenient subcutaneous (SQ) versions. The company's pipeline currently features two primary drug candidates: CLS-001, an improved biologic in preclinical development, targets Crohn's and Ulcerative Colitis; and CLS-002, also in preclinical stages, is an enhanced biologic aimed at various oncological indications. Established in 2014, Comera Life Sciences is based in Woburn, Massachusetts.